Microarray analysis carried out specifically in the CD34+ hematopoietic stem cells from the same set of patients supported this conclusion and a 38-gene signature that could distinguish patients who developed t-MDS/AML post-transplantation from those who did not was identified. The gene discussed is CD34; the disease is myelodysplastic syndrome.